July was a month of hard news and continuing progress in Huntington’s disease (HD) research. Tominersen showed that huntingtin can be lowered in people and has provided valuable lessons that will help guide the next generation of huntingtin-lowering therapies. No larger HD trial has followed, though Annexon tells us HD remains on its radar. A second study showed it could be given multiple times a year while staying under US and European radiation limits. This means that survey results may not always reflect the true picture, potentially affecting the accuracy of clinical trial results.